In the latest quarter, 16 analysts provided ratings for Intra-Cellular Therapies (NASDAQ:ITCI), showcasing a mix of bullish and bearish perspectives.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $97.06, a high estimate of $130.00, and a low estimate of $74.00. Marking an increase of 3.26%, the current average surpasses the previous average price target of $94.00.

Investigating Analyst Ratings: An Elaborate Study

A comprehensive examination of how financial experts perceive Intra-Cellular Therapies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

To gain a panoramic view of Intra-Cellular Therapies's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Intra-Cellular Therapies analyst ratings.

Unveiling the Story Behind Intra-Cellular Therapies

A Deep Dive into Intra-Cellular Therapies's Financials

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: Over the 3 months period, Intra-Cellular Therapies showcased positive performance, achieving a revenue growth rate of 46.44% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10.06%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -1.86%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Intra-Cellular Therapies's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.57%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: With a below-average debt-to-equity ratio of 0.02, Intra-Cellular Therapies adopts a prudent financial strategy, indicating a balanced approach to debt management.

What Are Analyst Ratings?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.